Hangzhou

Kinarus Therapeutics Announces Personnel Changes

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

Kinarus Therapeutics Announces Personnel Change

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity

Retrieved on: 
Tuesday, June 27, 2023
Knowledge, Drug development, Probability, Pioglitazone, Therapy, Humanitarian use licenses, Hangzhou, KNRS, Muthiri kinaru

Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (Hangzhou) Investment Management Co (CDIM), in Kinarus.

Key Points: 
  • Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (Hangzhou) Investment Management Co (CDIM), in Kinarus.
  • The bridge loans are immediately available and Kinarus can decide when to request delivery of funds, , depending on the settlement of the funds to be transfer from CDIM.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “While CDIM’s commitment to Kinarus has not waivered, there are customary bureaucratic and regulatory processes that need to be respected when Chinese groups invest abroad.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

2023 Global Esports Summit in China: Leading Speakers Kenneth Fok, Xu Haifeng, H.R.H Prince Faisal and Global Leaders Link to Future

Retrieved on: 
Wednesday, June 21, 2023
Entertainment, Sports, eSports, Other Entertainment, Technology, Other Technology, Electronic Games, Los Angeles Olympics, Road, ASEAN, Hangzhou, Legislative council, HKSAR, Tencent, Multimedia, National People's Congress, Asian Electronic Sports Federation, All-China Youth Federation, Congress, Shenzhen, Public Investment Fund, Hearing, Winner, Conference, Video game, Esports

Hosted by Tencent Esports, the 2023 Global Esports Summit and Tencent Esports Annual Conference will take place on 14th-15th July in the Shenzhen World Exhibition Center.

Key Points: 
  • Hosted by Tencent Esports, the 2023 Global Esports Summit and Tencent Esports Annual Conference will take place on 14th-15th July in the Shenzhen World Exhibition Center.
  • Themed “Link to Future”, the summit will discuss the future of the Esports industry, and release information related to the Asian Games Electronic Sports and the new Esports games by Tencent.
  • For the contestants of the very first Chinese national Esports team, his guidance will prove to be practical and timely.
  • H.R.H Prince Faisal bin Bandar bin Sultan Al Saud: Chairman of Saudi Esports Federation,Vice Chairman of Savvy Games Group.

State Grid Hangzhou Power Supply Unveils AI-Powered Service Team

Retrieved on: 
Friday, June 16, 2023
Djagaraga, State, AI, Game, Brain, Hangzhou, Mobile phone, Patch

HANGZHOU, China, June 16, 2023 /PRNewswire/ -- On June 15 at 10:27 AM, the intelligent monitor in the distribution network control hall at the power supply service command center of State Grid Hangzhou Power Supply Company ( "SGHPSC") issued a power outage alert. The alert signaled that the Gudang Substation 10 kV Zhaori 9674 line switch had tripped. Swiftly responding to the situation, the emergency repair expert promptly identified the affected area, and directed the repair crew to the location. Within one minute, Mr. Cai, a resident in the affected area, received a text message from the company notifying him about the outage. Simultaneously, the automated distribution system isolated the fault, restoring power to surrounding areas within three minutes. Approximately 20 minutes later, the company's emergency repair personnel arrived on-site. Notably, this was the first time where the power supplier utilized the virtual office platform, summoning digital workers to resolve a power outage. The virtual dispatcher, nicknamed Patch, granted permission for the crew to commence their work, ensuring swift resolution of the issue. Coinciding with these events, SGHPSC organized a mobilization meeting to mark the 100-day countdown to the Hangzhou Asian Games. During the meeting the company reaffirmed its commitment to do its part to assure that the classic event would take place without a hitch by ensuring a stable power supply.

Key Points: 
  • HANGZHOU, China, June 16, 2023 /PRNewswire/ -- On June 15 at 10:27 AM, the intelligent monitor in the distribution network control hall at the power supply service command center of State Grid Hangzhou Power Supply Company ( "SGHPSC") issued a power outage alert.
  • By seamlessly integrating these six "employees" into the power supply service command system, SGHPSC achieved a remarkable synergy between human expertise and digital capabilities.
  • This strategic approach ensures the team's ability to provide a secure and stable power supply while delivering optimized and efficient power services throughout the event.
  • With these measures in place, the AI-powered service team is fully prepared to meet the power demands and expectations of the Games, ensuring a seamless and successful event.

Kinarus Therapeutics Group Reports 2022 Annual Results

Retrieved on: 
Wednesday, May 31, 2023
Insurance, Maintenance, Therapy, File, D&O, Hangzhou, AMD, Annual, COVID-19, Tax, Federal Office of Public Health, FOPH, Federal, IP, KNRS, Consultant, Reverse takeover, Public health, Companion dog, Patient, Annual report, Research, IPF, CHF, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Cryptocurrency, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.
  • The reporting of audited financial results follows the announcement of the unaudited key financial figures published on 5 May 2023.
  • On 28 April 2023, Kinarus announced that the SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus’ 2022 annual report and asked Kinarus to report unaudited key financial figures for the year ended 31 December 2022.
  • To this end, Kinarus engaged Great Health Companion Group Ltd., to explore financing and partnering options for KIN001 in China.

Global Bioabsorbable Stents (BAS) Pipeline Report 2023: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Pharmaceutical, Health, Medical Devices, Biotechnology, Hangzhou, Cryptocurrency

5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview

Key Points: 
  • 5.12 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
    5.14 Japan Stent Technology Co., Ltd. Company Overview
    6.1 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
    6.2 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023
    6.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022
    6.4 Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022

Roan Holdings Group Co., Ltd. Reports Fiscal Year 2022 Financial Results

Retrieved on: 
Monday, May 15, 2023
Interest, Hangzhou, LCOS, COVID-19, G&A, Roan, Maccabi Healthcare Services, Local government, Limited partnership, The May Department Stores Company, RMB, Cryptocurrency, Airline, Rare-earth element, Security (finance), New materials in 20th-century art, PRC

Revenue from consulting services relating to debt collection was $nil for the year ended December 31, 2022, as compared to $206,792 for the same period of last fiscal year.

Key Points: 
  • Revenue from consulting services relating to debt collection was $nil for the year ended December 31, 2022, as compared to $206,792 for the same period of last fiscal year.
  • Revenue from the healthcare service was $6,928 and $nil for the year ended December 31, 2022 and 2021, respectively.
  • Commission and fees on financial guarantee services was $317,857 and $456,944 for the years ended December 31, 2022 and 2021, respectively.
  • The provisions for financial guarantee services are related to the financial guarantee service business as per the requirement of local government.

Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management

Retrieved on: 
Thursday, May 11, 2023
MAP, Idiopathic disease, Partnership, Idiopathic pulmonary fibrosis, Drug development, Therapy, Probability, Hangzhou, AMD, KNRS, HIV disease progression rates, Patent, Patient, Disease, Knowledge, Mortality, API, IPF, Pioglitazone, CHF, Humanitarian use licenses, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China (“CDIM”).

Key Points: 
  • Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China (“CDIM”).
  • Under the terms of the loan agreement, CDIM grants a subordinated loan in the amount of CHF 1.5 million to Kinarus for a fixed term of three years without any interest.
  • During the term of the agreement, the outstanding loan amount can be converted at any time into Kinarus shares with a nominal value of CHF 0.01 at a fixed conversion price of CHF 0.01 per Kinarus share.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration

Retrieved on: 
Monday, May 8, 2023
Eribulin, Senior, Hangzhou, HER2, Breast, Antibody, USD, Lung, Patient, ADC, Spacecraft, Phase, Breast cancer, Pharmaceutical industry, Eisai

TOKYO, May 8, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.

Key Points: 
  • TOKYO, May 8, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration.
  • Under a license agreement signed by the two companies in 2018, Eisai has granted BlissBio global exclusive development rights for several ADCs to use eribulin as the payload.
  • Under the terms of the joint development agreement, Eisai will make upfront and development milestone payments to BlissBio, conduct a Phase II clinical trial in breast cancer, and obtain option rights to develop and commercialize BB-1701 globally, excluding Greater China (China, Hong Kong, Macau, Taiwan).
  • If all development, regulatory and sales milestones are achieved, up to a total of $2 billion USD will be paid.